Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

PFS better with trofosfamide than doxorubicin in elderly patients with untreated metastatic soft-tissue sarcomas

Hartman JT et al. ASCO 2018, Abstract 11507.

Key clinical point: The oral alkylating agent trofosfamide showed efficacy in a small number of elderly patients with untreated metastatic soft-tissue sarcomas.

Major finding: In a randomized phase 2 trial that compared trofosfamide with doxorubicin (Adriamycin), the 6-month progression-free survival (PFS) rate with trofosfamide, the primary endpoint, was 27. 6% versus 35.9% in the doxorubicin arm.

Study details: Randomized phase 2 trial comparing trofosfamide with doxorubicin in 120 elderly patients with histologically confirmed metastatic soft-tissue sarcomas with no prior first-line chemotherapy and with adequate bone marrow, renal, and liver functionelderly patients with previously untreated .

Disclosures: The trial was supported by Baxter Oncology of Germany. Dr. Hartmann reported having no conflicts of interest to disclose.

Source: Hartman JT et al. ASCO 2018, Abstract 11507.

Citation:

Hartman JT et al. ASCO 2018, Abstract 11507.

This Week's Must Reads

Broad opioid legislation advances in Congress, Senate floor debate, Sept. 17, 2018

Early supportive care cuts costs related to curative treatment, Koprowski CD et al. 2018 ASCO Quality Care Symposium, Abstract 142

Employee deductibles outstrip wages, Kaiser Family Foundation, 2018 Employer Health Benefits

The financial burden of metastatic breast cancer, Wheeler SB et al. Quality Care Symposium, Abstract 32

Must Reads in Sarcoma & GIST

Nivolumab, pembrolizumab successfully used in Kaposi sarcoma, Galanina et al. Cancer Immunol Res. 2018 Sept 7. doi: 10.1158/2326-6066.CIR-18-0121.

Perioperative radiation therapy underused in elderly patients with soft tissue sarcomas, Venigalla S et al. Intl J Rad Oncology*Biology*Physics; September (102) 2018: 155-165. https://doi.org/10.1016/j.ijrobp.2018.05.019

Age, R0 resection, and adjuvant radiotherapy boost outcomes in myxofibrosarcoma, Boughzala-Bennadji R et al. Intl J Rad Oncology*Biology*Physics; October (102) 2018: 399-406. https://doi.org/10.1016/j.ijrobp.2018.05.055

Tumor size, invasion beyond subcutaneous fat predict adverse outcomes in undifferentiated pleomorphic sarcoma, Winchester D et al. J Am Acad Dermatol. Available online 19 May 2018 https://doi.org/10.1016/j.jaad.2018.05.022

High recurrence rate after pancreaticoduodenectomy for primary retroperitoneal sarcoma, Tseng W et al. European Journal of Surgical Oncology 2018 (44): June; 810-815.